Biotech News
Related news
CORTCorcept2026-07-22 20:05 EST
Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-04-23 20:05 EST
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
VKTXViking Therapeutics2026-10-28 20:05 EST
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
VKTXViking Therapeutics2026-07-29 20:05 EST
Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NBIXNeurocrine Biosciences2026-10-12 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
NBIXNeurocrine Biosciences2026-07-09 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
CRNXCrinetics Pharmaceuticals2026-01-26 22:00 EST
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
AMPHAmphastar Pharmaceuticals, Inc.2020-10-29 20:05 EST
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
CRNXCrinetics Pharmaceuticals2026-06-30 20:05 EST
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
AMPHAmphastar Pharmaceuticals, Inc.2021-04-29 10:00 EST
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
Corcept
Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...
Recent company news
CORTCorcept2026-11-03 21:05 EST
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
CORTCorcept2026-10-27 20:05 EST
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
CORTCorcept2026-10-26 12:00 EST
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
CORTCorcept2026-10-20 20:00 EST
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
CORTCorcept2026-09-23 12:00 EST
Corcept Announces Planned Leadership Transition
Stock data
- Close
- 71.63 USD
- Market cap
- 7.64B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States